Clinical Trials Logo
  1. Home
  2. Other
  3. NCT03639467

Study of Anlotinib Combined With Gemcitabine/Cisplatin in Advanced Nasopharyngeal Carcinoma

Recurrent Nasopharyngeal Carcinoma Clinical Trial

Official title:
Phase Ib / II Study of Anlotinib Combined With Gemcitabine/Cisplatin in Previous Untreated Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Clinical Trial Summary

Gemcitabine plus cisplatin (GC) is more effective than fluorouracil plus cisplatin in the treatment of recurrent or metastatic NPC (R/M-NPC). GC is the standard first-line chemotherapy regimen for this population. However, the median progression-free survival was only 7 months for GC regimen. Anlotinib is a kinase inhibitor of receptor tyrosine with multi-targets, especially for VEGFR2、VEGFR3、PDGFRβ and c-Kit, which has strong effect of anti-angiogenesis. This study is aim to evaluate the efficacy and safety of the combination regimen of anlotinib plus GC as first-line treatment for R/M-NPC.

Clinical Trial Description

In the phase Ib portion, an escalated dose cohort is recruited to determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of anlotinib when given in combination with gemcitabine/cisplatin. The phase II portion is designed to characterize the efficacy and safety of the combination therapy in previous untreated patients with R/M-NPC. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03639467
Study type Interventional
Source Chinese Academy of Medical Sciences
Contact Yuankai Shi, MD
Phone +86 10 87788293
Email syuankaipumc@126.com;
Status Recruiting
Phase Phase 1/Phase 2
Start date September 18, 2018
Completion date August 15, 2023
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06010095 - Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer Phase 2
Recruiting NCT06029270 - Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer Phase 2
Recruiting NCT03666221 - Nimotuzumab for Recurrent Nasopharyngeal Carcinoma Phase 2
Recruiting NCT05350891 - Transnasal Endoscopic Surgery Combined With Adjuvant Immunotherapy for Recurrent NPC Phase 2
Active, not recruiting NCT04586088 - Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure Phase 2
Active, not recruiting NCT04405622 - Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma. Phase 2
Recruiting NCT06235203 - Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC Phase 3
Not yet recruiting NCT04215510 - Early Recurrent Nasopharyngeal Cancer: the Effect of Surgery vs IMRT Phase 3
Recruiting NCT03930498 - Programmed Death-1 (PD-1) Antibody Combined With Chemoradiotherapy in High-risk Recurrent Nasopharyngeal Carcinoma Phase 2
Recruiting NCT03907826 - PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients Phase 3
Recruiting NCT04376866 - Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma Phase 3
Not yet recruiting NCT05432219 - A Transoral Retropterygoid Approach to Resect Recurrent Nasopharyngeal Carcinoma N/A
Recruiting NCT04425265 - Plasma Radiofrequency Ablation at Low Temperature Versus Electrocautery Block Resection at High Frequency for Localized Recurrent Nasopharyngeal Carcinoma N/A
Not yet recruiting NCT03689556 - Examine the Prognostic Role of FLT PET/CT for Patients With LR-NPC Treated by Carbon Ion Therapy
Not yet recruiting NCT03210389 - A Clinical Trial of Chemotherapy With Lobaplatin and 5-FU in Recurrent Local or Distant Advanced NPC. Phase 2
Completed NCT01370070 - MK-2206 in Recurrent Nasopharyngeal Carcinoma Phase 2
Completed NCT01392235 - Famitinib in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma (NPC) Phase 2
Not yet recruiting NCT06228079 - Adjuvant vs Surgery Only in Early-stage Recurrent NPC Phase 3
Terminated NCT04458909 - Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer Phase 3
Withdrawn NCT04231864 - Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer Phase 2